Reductions in low-density lipoprotein (LDL) cause a decline in lipoprotein-associated phospholipase A2 (Lp-PLA2) activity, which limits the predictive value of Lp-PLA2 in patients undergoing lipid-lowering therapy.

Authors

• Person: Not available Organization: National Lipid Association
  EBM Tools for Practice: Best Biomarkers for Inflammation

Sources

• EBM Tools for Practice: Best Biomarkers for Inflammation www.lipid.org National Lipid Association via serper

Referenced by nodes (1)

• low-density lipoprotein cholesterol concept